MultiCell Technologies Inc (MCET)

[TPX]

Global Next-generation Antibody Therapies Market Forecast 2017-2027

June 19, 2017

LONDON, Jun 19, 2017 (PR Newswire Europe via COMTEX) -- LONDON, June 19, 2017 /PRNewswire/ --

Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new249-page reportyou will receive133 charts- all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market [https://www.visiongain.com/Sector/8/Pharma ].

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

-Global Next-Generation Antibody Therapies Market forecastsfrom2017-2027

- Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the followingfive submarkets: - Antibody-drug conjugates (ADCs) - Engineered antibodies - Bispecific antibodies - Antibody fragments and antibody-like proteins (ALPs) - Biosimilar antibody therapies

- How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecastsindividual revenues of seven products: - Adcetris - Kadcyla - Gazyva/Gazyvaro - Poteligeo - Removab - Blincyto - Kalbitor

- Our analyses show individual revenue forecasts to 2027 for theseregional markets: - US - EU5 group - Asia-Pacific region - Latin America - Rest of the World

- This report discussesissues affecting the next-generation antibody therapies market: - R&D for next generation antibodies - explore technologies and potentials - Challenges with current monoclonal antibody (mAb) therapies - Big pharma companies investing in next-generation antibody research and development - Biosimilars and their effects on the next-generation antibody therapies market

- Our study discussesstrengths, weaknesses, opportunities and threats as well as social, technological, economic and political factorsthat affect the next-generation antibody therapies market

Visiongain [https://www.visiongain.com ]'s study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report todayGlobal Next-Generation Antibody Therapies Market Forecast 2017-2027 [https://www.visiongain.com/Report/1881/Global-Next-Generation-Antibody-Therapies-Market-Forecast-2017-2027 ] : Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

To request a report overview of this report please email Sara Peerun at [e-mail] or call Tel: [phone]

Or click on http://bit.ly/2tv4WQN

Companies and Organizations Mentioned in the Report

... MultiCell Immunotherapeutics (MCIT) ...

http://www.marketwatch.com/story/global-next-generation-antibody-therapies-market-forecast-2017-2027-2017-06-19-9203218